Collaboration between community and academic oncologists is crucial for enrolling patients in clinical trials. Dr. Gautam Jha, MD, the medical director of M Health Fairview Masonic Cancer Clinic, highlights the benefits of such partnerships. One example he cites is the successful accrual of patients to the phase 3 ECLIPSE trial (NCT05204927) at the University of Minnesota and surrounding community cancer centers.
The ECLIPSE trial compared the radioligand 177Lu-PSMA-I&T to standard hormone therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). This novel treatment approach targets prostate-specific membrane antigen (PSMA) and offers a less toxic alternative to conventional therapies. Importantly, it delays the need for chemotherapy, providing patients with a preferable treatment option.
Dr. Jha emphasizes the importance of collaboration in facilitating trial accrual. By addressing common patient needs and reducing logistical burdens, the partnership between academic and community oncologists ensures that patients have access to cutting-edge research. Despite the challenges faced by community oncologists in enrolling patients in trials, proactive engagement and leveraging professional networks can help overcome these barriers.
Bridging the gap between academic and community oncologists not only benefits patients but also enhances professional satisfaction among referring physicians. By offering innovative treatments locally, referring physicians can maintain patient continuity and contribute to advancements in medical knowledge. Dr. Jha’s experience underscores the effectiveness of collaborative approaches in improving trial accrual rates and advancing patient care.
